Answers are grounded in this paper and cite their sources.
Observational analysis highlights the role of lipoprotein(a) in cardiovascular risk, suggesting genetic links matter.
Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein variant composed of an LDL-like particle (containing apolipoprotein B-100) covalently bound to apolipoprotein(a). The apo(a) component contains multiple plasminogen-like kringle domains (especially variable copies of kringle IV type 2), and carries oxidized phospholipids (OxPL) that confer proinflammatory and pro-atherogenic properties[1]. Plasma Lp(a) levels are highly heritable (>70–90% determined by the LPA gene) and remain essentially constant after early childhood[2]. Approximately 20–25% of people worldwide have an “elevated” Lp(a) (typically defined as ≥50 mg/dL or ≥125 nmol/L)[2][3]. Levels vary by ethnicity: persons of African ancestry have substantially higher median Lp(a) than Caucasians or Asians[2]. Because Lp(a) levels are stable over life (aside from acute illness or kidney/liver disease[2]), a single measurement in early adulthood has been recommended for lifetime risk assessment[1].
No takes yet. Share an insight, caveat, or question.
Thakur et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: